| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GP25L2 |
| Uniprot No | Q9BVK6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 40-197aa |
| 氨基酸序列 | FHIGETEKKCFIEEIPDETMVIGNYRTQLYDKQREEYQPATPGLGMFVEVKDPEDKVILARQYGSEGRFTFTSHTPGEHQICLHSNSTKFSLFAGGMLRVHLDIQVGEHANDYAEIAAKDKLSELQLRVRQLVEQVEQIQKEQNYQRWREERFRQTSE |
| 预测分子量 | 45.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GP25L2重组蛋白的3篇假设性参考文献(注：GP25L2可能为虚构或非标准命名，以下内容基于常见研究方向模拟)：
1. **《Recombinant GP25L2 enhances lysosomal lipid metabolism in vitro》**
- **作者**: Chen, X. et al. (2019)
- **摘要**: 研究通过大肠杆菌系统表达GP25L2重组蛋白，发现其能激活溶酶体中的酶活性，促进鞘脂代谢，可能用于溶酶体贮积病的治疗。
2. **《Structural and functional analysis of GP25L2 in membrane repair》**
- **作者**: Müller, R. & Park, S. (2021)
- **摘要**: 解析GP25L2的晶体结构，揭示其通过结合细胞膜脂质参与膜修复过程，重组蛋白在体外实验中显著减少氧化应激导致的膜损伤。
3. **《GP25L2 recombinant protein mitigates neurodegeneration in a mouse model》**
- **作者**: Gupta, A. et al. (2022)
- **摘要**: 在小鼠模型中验证GP25L2重组蛋白的神经保护作用，表明其通过调控自噬通路延缓帕金森病相关神经退行性病变。
**备注**：GP25L2可能为特定文献中的非通用命名，建议结合具体研究背景或确认标准蛋白名称(如Prosaposin/Saposin相关蛋白)进一步检索。
**Background of GP25L2 Recombinant Protein**
GP25L2 (Glycolipid Transfer Protein-like 2), also known as GLTPD2. is a member of the glycolipid transfer protein (GLTP) family, characterized by its ability to bind and transport glycolipids. This soluble protein is evolutionarily conserved and shares structural homology with GLTP, featuring a unique folding pattern termed the GLTP fold, which facilitates lipid recognition and transfer. GP25L2 is encoded in humans by the *GLTPD2* gene, located on chromosome 12. and is expressed in various tissues, including the brain, liver, and immune cells.
Functionally, GP25L2 is implicated in glycolipid metabolism and membrane dynamics. It selectively interacts with glycosphingolipids, such as ceramide and glucosylceramide, playing roles in lipid homeostasis, cell signaling, and membrane trafficking. Studies suggest its involvement in immune regulation, neurodevelopment, and apoptosis, though its precise mechanisms remain under investigation. Dysregulation of glycolipid metabolism is linked to pathologies like lysosomal storage disorders, neurodegenerative diseases, and cancer, highlighting GP25L2's potential relevance in these contexts.
The recombinant form of GP25L2 is typically produced using bacterial (e.g., *E. coli*) or mammalian expression systems to ensure proper folding and post-translational modifications. Purification methods often employ affinity tags (e.g., His-tag) for high yield and purity. Recombinant GP25L2 serves as a vital tool for *in vitro* studies, enabling researchers to dissect lipid-protein interactions, screen therapeutic compounds, and explore its structural biology via techniques like X-ray crystallography or NMR.
Current research focuses on elucidating GP25L2's role in disease pathways and its utility as a biomarker or therapeutic target, particularly in lipid-associated disorders. Its recombinant availability accelerates functional studies, bridging gaps in understanding glycolipid-mediated cellular processes.
×
